FIGURE 5.
Immune signature was associated with the TML in colon cancer. Tumor mutation load (A) and neoantigen counts (B) in colon cancer samples were compared with the immune risk signature group. (C) Distribution of mutational load in non-MSI samples were also assessed between high-risk and low-risk subtypes. (D) Mutational exposures (number of mutations) were attributed to each mutation signature. (E) The mutational activities of corresponding extracted mutational signatures (signature 1, 6, and 10, named as COSMIC database). (F) Multivariate Logistic regression analysis of TML with respect to immune signature was adjusted by taking into account age, gender, stage, and mutational signatures. P values as indicated (Wilcoxon rank-sum test).